Edition:
United States

Incyte Corp (INCY.O)

INCY.O on Nasdaq

84.34USD
1:30pm EST
Change (% chg)

$1.01 (+1.21%)
Prev Close
$83.33
Open
$83.73
Day's High
$84.53
Day's Low
$83.28
Volume
601,979
Avg. Vol
1,671,973
52-wk High
$96.33
52-wk Low
$57.00

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $17,836.65
Shares Outstanding(Mil.): 214.05
Dividend: --
Yield (%): --

Financials

  INCY.O Industry Sector
P/E (TTM): 165.31 85.34 35.95
EPS (TTM): 0.50 -- --
ROI: 5.28 10.06 12.64
ROE: 6.16 10.28 13.82

Incyte loses trade-secret case against Flexus over cancer drug

A Delaware state court jury has rejected pharmaceutical company Incyte Corp's claims that rival Flexus Biosciences Inc was unjustly enriched by stealing cancer drug research trade secrets from it before Bristol-Myers Squibb Co acquired Flexus in 2015.

Nov 08 2018

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC

Oct 19 2018

Earnings vs. Estimates